Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's Lymphoma: a systematic review and economic evaluation

Beverley Wake; Christopher Hyde; Stirling Bryan; Pelham Barton; Fujian Song; Anne Fry-Smith; Clare Davenport

Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's Lymphoma: a systematic review and economic evaluation

Beverley Wake, Christopher Hyde, Stirling Bryan, Pelham Barton, Fujian Song, Anne Fry-Smith, Clare Davenport

Applied Health Research

Research output: Contribution to journal › Article

21 Citations (Scopus)

Original language	English
Pages (from-to)	1-85
Number of pages	85
Journal	Health Technology Assessment
Volume	6
Issue number	3
Publication status	Published - 1 Jan 2002

Cite this

@article{9f352e49cb844514946cde910809a82f,

title = "Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's Lymphoma: a systematic review and economic evaluation",

author = "Beverley Wake and Christopher Hyde and Stirling Bryan and Pelham Barton and Fujian Song and Anne Fry-Smith and Clare Davenport",

year = "2002",

month = jan,

day = "1",

language = "English",

volume = "6",

pages = "1--85",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "NIHR Health Technology Assessment Programme",

number = "3",

}

TY - JOUR

T1 - Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's Lymphoma: a systematic review and economic evaluation

AU - Wake, Beverley

AU - Hyde, Christopher

AU - Bryan, Stirling

AU - Barton, Pelham

AU - Song, Fujian

AU - Fry-Smith, Anne

AU - Davenport, Clare

PY - 2002/1/1

Y1 - 2002/1/1

M3 - Article

C2 - 12022936

SN - 2046-4924

VL - 6

SP - 1

EP - 85

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 3

ER -